Aldeyra eyes the future
A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
Astra and Sanofi’s RSV jab takes a step towards market
A pivotal win puts nirsevimab on track to be filed next year, but the reimbursement hurdle looms.
Bristol’s Tyk2 ticks the boxes
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Macrogenics takes another shot at a novel immune checkpoint
Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.
Valneva joins the phase 3 Covid-19 vaccine club
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
AAN 2021 – Helios backs Alnylam’s sunny forecasts
Full data from the Helios-A trial support vutrisiran’s profile as a more convenient Onpattro, though that’s probably as good as it gets.
